Trial · NCT02949219
Adverse events66
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 66
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Pembrolizumab) | 2 | 40 | 4 |
| other | Endocrine disorders - Other, specify | Endocrine disorders | Treatment (Pembrolizumab) | 1 | 40 | 3 |
| other | Hyperthyroidism | Endocrine disorders | Treatment (Pembrolizumab) | 6 | 40 | 10 |
| other | Hypothyroidism | Endocrine disorders | Treatment (Pembrolizumab) | 11 | 40 | 45 |
| other | Abdominal distension | Gastrointestinal disorders | Treatment (Pembrolizumab) | 1 | 40 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Pembrolizumab) | 3 | 40 | 7 |
| other | Ascites | Gastrointestinal disorders | Treatment (Pembrolizumab) | 1 | 40 | 1 |
| other | Constipation | Gastrointestinal disorders | Treatment (Pembrolizumab) | 1 | 40 | 2 |
| other | Dysphagia | Gastrointestinal disorders | Treatment (Pembrolizumab) | 1 | 40 | 1 |
| other | Nausea | Gastrointestinal disorders | Treatment (Pembrolizumab) | 1 | 40 | 1 |
| other | Fatigue | General disorders | Treatment (Pembrolizumab) | 3 | 40 | 7 |
| other | Localized edema | General disorders | Treatment (Pembrolizumab) | 1 | 40 | 9 |
| other | Infections and infestations - Oth spec | Infections and infestations | Treatment (Pembrolizumab) | 1 | 40 | 2 |
| other | Papulopustular rash | Infections and infestations | Treatment (Pembrolizumab) | 2 | 40 | 2 |
| other | Sepsis | Infections and infestations | Treatment (Pembrolizumab) | 1 | 40 | 1 |
| other | Fall | Injury, poisoning and procedural complications | Treatment (Pembrolizumab) | 1 | 40 | 1 |
| other | Alanine aminotransferase increased | Investigations | Treatment (Pembrolizumab) | 11 | 40 | 33 |
| other | Alkaline phosphatase increased | Investigations | Treatment (Pembrolizumab) | 28 | 40 | 97 |
| other | Aspartate aminotransferase increased | Investigations | Treatment (Pembrolizumab) | 20 | 40 | 39 |
| other | Blood bilirubin increased | Investigations | Treatment (Pembrolizumab) | 7 | 40 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02949219/events